CA3247273A1 - CRYSTALLINE FORM OF LANIFIBRANOR - Google Patents

CRYSTALLINE FORM OF LANIFIBRANOR

Info

Publication number
CA3247273A1
CA3247273A1 CA3247273A CA3247273A CA3247273A1 CA 3247273 A1 CA3247273 A1 CA 3247273A1 CA 3247273 A CA3247273 A CA 3247273A CA 3247273 A CA3247273 A CA 3247273A CA 3247273 A1 CA3247273 A1 CA 3247273A1
Authority
CA
Canada
Prior art keywords
lanifibranor
beta
form beta
crystalline form
pxrd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3247273A
Other languages
English (en)
French (fr)
Inventor
Frédéric BELL
Benaissa Boubia
Original Assignee
Inventiva SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inventiva SA filed Critical Inventiva SA
Publication of CA3247273A1 publication Critical patent/CA3247273A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
CA3247273A 2022-04-05 2023-04-04 CRYSTALLINE FORM OF LANIFIBRANOR Pending CA3247273A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22305456.0 2022-04-05
EP22305456 2022-04-05
PCT/EP2023/058743 WO2023194339A1 (en) 2022-04-05 2023-04-04 Crystalline form of lanifibranor

Publications (1)

Publication Number Publication Date
CA3247273A1 true CA3247273A1 (en) 2023-10-12

Family

ID=81326293

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3247273A Pending CA3247273A1 (en) 2022-04-05 2023-04-04 CRYSTALLINE FORM OF LANIFIBRANOR

Country Status (14)

Country Link
US (1) US20250243192A1 (cg-RX-API-DMAC7.html)
EP (1) EP4504725A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025511847A (cg-RX-API-DMAC7.html)
KR (1) KR20250002337A (cg-RX-API-DMAC7.html)
CN (1) CN119301120A (cg-RX-API-DMAC7.html)
AR (1) AR128985A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023250118A1 (cg-RX-API-DMAC7.html)
CA (1) CA3247273A1 (cg-RX-API-DMAC7.html)
IL (1) IL316075A (cg-RX-API-DMAC7.html)
MX (1) MX2024012348A (cg-RX-API-DMAC7.html)
PY (1) PY2324870A (cg-RX-API-DMAC7.html)
TW (1) TW202404966A (cg-RX-API-DMAC7.html)
UY (1) UY40216A (cg-RX-API-DMAC7.html)
WO (1) WO2023194339A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022325334A1 (en) * 2021-08-12 2024-02-22 Inventiva Crystal form of lanifibranor, preparation method therefor, and use thereof
JP2026501899A (ja) 2023-01-19 2026-01-16 インベンティバ ラニフィブラノール製剤
WO2024251730A1 (en) 2023-06-05 2024-12-12 Inventiva Lanifibranor for use in the treatment of splanchnic vasodilatation in a patient with a liver condition
AR133887A1 (es) * 2023-09-22 2025-11-12 Inventiva Método de fabricación de lanifibranor
IL330214A (en) 2023-12-21 2026-08-01 Inventiva Combination therapy for the prevention and/or treatment of liver disease
AU2024409290A1 (en) 2023-12-21 2026-08-06 Inventiva Combination therapy for the prevention and/or the treatment of a liver disease
WO2025191292A1 (en) 2024-03-15 2025-09-18 Inventiva Methods and monitoring of treatment with lanifibranor
WO2025191117A1 (en) 2024-03-15 2025-09-18 Inventiva Prevention of blood disorders in patient treated with a ppar agonist
TW202604485A (zh) 2024-05-17 2026-02-01 法商因文帝華公司 患有肝損傷患者肝疾病之治療
WO2026115290A1 (en) 2024-11-28 2026-06-04 Inventiva Non-invasive monitoring of nash treatment with lanifibranor
WO2026125286A1 (en) 2024-12-09 2026-06-18 Inventiva Combinations comprising lanifibranor and a glp-1/gip/glucagon triple receptor agonist for use in the treatment of liver diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2890071B1 (fr) 2005-08-30 2007-11-09 Fournier Sa Sa Lab Nouveaux composes de l'indole
WO2022122014A1 (zh) 2020-12-11 2022-06-16 苏州科睿思制药有限公司 Lanifibranor的晶型及其制备方法和用途
WO2022143479A1 (zh) 2020-12-29 2022-07-07 广东东阳光药业有限公司 一种化合物的固体形式及其制备方法和用途
US20240246949A1 (en) 2021-06-10 2024-07-25 Teva Pharmaceuticals International Gmbh Solid state forms of lanifibranor and process for preparation thereof
CN115466252A (zh) 2021-06-11 2022-12-13 上海希迈医药科技有限公司 一种Lanifibranor的晶型及其制备方法
AU2022325334A1 (en) 2021-08-12 2024-02-22 Inventiva Crystal form of lanifibranor, preparation method therefor, and use thereof

Also Published As

Publication number Publication date
MX2024012348A (es) 2024-11-08
JP2025511847A (ja) 2025-04-16
EP4504725A1 (en) 2025-02-12
WO2023194339A1 (en) 2023-10-12
TW202404966A (zh) 2024-02-01
UY40216A (es) 2023-10-31
IL316075A (en) 2024-12-01
PY2324870A (es) 2023-10-27
CN119301120A (zh) 2025-01-10
US20250243192A1 (en) 2025-07-31
KR20250002337A (ko) 2025-01-07
AR128985A1 (es) 2024-07-03
AU2023250118A1 (en) 2024-10-17

Similar Documents

Publication Publication Date Title
US20250243192A1 (en) Crystalline form of lanifibranor
US10167247B2 (en) Solid forms of treprostinil
EP3453703B1 (en) Crystalline form e of tafamidis meglumine, process for preparation and use thereof
NO341039B1 (no) Farmasøytisk sammensetning omfattende en polymorf form av 3-(4-amino-1-okso-1,3 dihydro-isoindol-2-yl)-piperidin-1,6-dion
KR102442536B1 (ko) 리나글립틴 결정형 및 이의 제조방법
EP3022209B1 (en) Dolutegravir potassium salt
KR20200138283A (ko) 결정질 형태, 및 결정질 형태의 화합물을 제조하는 방법
FI76330B (fi) Foerfarande foer framstaellning av terapeutiskt aktivt -monohydrat av (+)-katekin.
EP3656768A1 (en) Beraprost-314d crystals and methods for preparation thereof
EP3650444A1 (en) Salt and polymorph of benzopyrimidinone compound and pharmaceutical composition and use thereof
JP5669748B2 (ja) 11−(2−ピロリジン−1−イル−エトキシ)−14,19−ジオキサ−5,7,26−トリアザ−テトラシクロ[19.3.1.1(2,6).1(8,12)]ヘプタコサ−1(25),2(26),3,5,8,10,12(27),16,21,23−デカエンクエン酸塩
CN112142737B (zh) 一种治疗精神分裂症药物盐酸盐的固体形式
EP2977372A1 (en) Polymorphs of febuxostat
EP3656767A1 (en) Beraprost-314d monohydrate crystals and methods for preparation thereof
EA052550B1 (ru) Кристаллическая форма ланифибранора
US20100113550A1 (en) New Crystal Forms
US9388113B2 (en) Salts of sitagliptin, process from the preparation and pharmaceutical composition therefore
HK40120719A (en) Crystalline form of lanifibranor
CN112538123A (zh) 一种舒更葡糖钠晶型m
EP3181565A1 (en) Crystalline omarigliptin salts
WO2018172950A1 (en) Anhydrous crystalline forms of sodium (s)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinolinecarboxylate
WO2026046981A1 (en) Solid forms of 5-[3-[[(3r)-1-ethyl-3-piperidyl]amino]-5-methyl-1,2,4-triazin-6-yl]-2,3- dihydrobenzofuran-4-ol
TW202333694A (zh) 稠環衍生物的晶型、其製備方法及其應用
WO2014147641A2 (en) Sitagliptin pterostilbene phosphate salt, process for the preparation and pharmaceutical composition thereof

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20241001

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20241002

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241002

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241002

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250213

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250324

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250324

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250324

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260324

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260324